Q3 EPS Estimate for Spero Therapeutics Lifted by Analyst

Spero Therapeutics, Inc. (NASDAQ:SPRO) – Research analysts at HC Wainwright raised their Q3 2024 EPS estimates for shares of Spero Therapeutics in a note issued to investors on Monday, November 4th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of $0.02 for the quarter, up from their prior forecast of ($0.38). HC Wainwright currently has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Spero Therapeutics’ current full-year earnings is ($1.59) per share. HC Wainwright also issued estimates for Spero Therapeutics’ Q4 2024 earnings at ($0.21) EPS, FY2024 earnings at ($0.75) EPS, Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at $0.10 EPS and FY2025 earnings at ($0.33) EPS.

Spero Therapeutics (NASDAQ:SPRO) last issued its earnings results on Monday, August 5th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. Spero Therapeutics had a return on equity of 25.67% and a net margin of 14.74%. The firm had revenue of $10.20 million for the quarter, compared to the consensus estimate of $9.80 million. During the same quarter in the previous year, the company posted ($0.23) earnings per share.

Several other equities analysts have also weighed in on SPRO. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Spero Therapeutics in a research report on Tuesday, August 6th. TD Cowen upgraded shares of Spero Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th.

Spero Therapeutics Price Performance

Shares of Spero Therapeutics stock opened at $1.31 on Wednesday. The firm has a market cap of $70.73 million, a price-to-earnings ratio of 3.97 and a beta of 0.63. The stock has a 50-day simple moving average of $1.30 and a 200-day simple moving average of $1.37. Spero Therapeutics has a 52-week low of $1.01 and a 52-week high of $1.89.

Hedge Funds Weigh In On Spero Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC acquired a new position in shares of Spero Therapeutics during the 1st quarter worth about $31,000. Renaissance Technologies LLC increased its position in Spero Therapeutics by 14.2% in the 2nd quarter. Renaissance Technologies LLC now owns 975,952 shares of the company’s stock worth $1,269,000 after buying an additional 121,492 shares during the period. Acadian Asset Management LLC lifted its holdings in shares of Spero Therapeutics by 121.8% during the first quarter. Acadian Asset Management LLC now owns 762,598 shares of the company’s stock worth $1,310,000 after buying an additional 418,742 shares during the last quarter. Murchinson Ltd. boosted its position in shares of Spero Therapeutics by 1.3% in the first quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock valued at $1,503,000 after acquiring an additional 11,210 shares during the period. Finally, Vanguard Group Inc. grew its stake in shares of Spero Therapeutics by 0.6% in the first quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock worth $2,844,000 after acquiring an additional 9,675 shares during the last quarter. Institutional investors and hedge funds own 25.60% of the company’s stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.